The DOI matches its Crossref record.
St. John's Wort in Mild to Moderate Depression: The Relevance of Hyperforin for the Clinical Efficacy
Abstract
In a randomized, double-blind, placebo-controlled, multicenter study, the clinical efficacy and safety of two different extracts of St. John's wort were investigated in 147 male and female outpatients suffering from mild or moderate depression according to DSM-IV criteria. Following a placebo run-in period of three to seven days, the patients were randomized to one of three treatment groups: During the 42-day treatment period, they received 3 x 1 tablets of either placebo, Hypericum extract WS 5573 (300 mg, with a content of 0.5% hyperforin), or Hypericum extract WS 5572 (300 mg, with a content of 5% hyperforin). The manufacturing process for the two Hypericum preparations was identical, so that they differed only in their hyperforin content. Efficacy regarding depressive symptoms was assessed on days 0, 7, 14, 28, and 42, using the Hamilton Rating Scale for Depression (HAMD, 17-item version) and the Depression Self-Rating Scale (D-S) according to von Zerssen. In addition, the severity of illness was also rated by the investigators on days 0 and 42 using the Clinical Global Impression (CGI) scale. The last observation of patients withdrawn from the trial prematurely was carried forward. At the end of the treatment period (day 42), the patients receiving WS 5572 (5% hyperforin) exhibited the largest HAMD reduction versus day 0 (10.3 +/- 4.6 points; mean +/- SD), followed by the WS 5573 group (0.5% hyperforin; HAMD reduction 8.5 +/- 6.1 points) and the placebo group (7.9 +/- 5.2 points). As regards the change in the HAMD total score between day 0 and treatment end and its relationship to the hyperforin dose, a significant monotonic trend was demonstrated in the Jonckheere-Terpstra test (p = 0.017). In pairwise comparisons, WS 5572 (5% hyperforin) was superior to placebo in alleviating depressive symptoms according to HAMD reduction (Mann-Whitney U-test: p = 0.004), whereas the clinical effects of WS 5573 (0.5% hyperforin) and placebo were descriptively comparable. These results show that the therapeutic effect of St. John's Wort in mild to moderate depression depends on its hyperforin content.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Calixto, J. B. (2000) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2000000200004 · Cited by 1,282
St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., Serabjit-Singh, C. J., Willson, T. M., Collins, J. L., & Kliewer, S. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130155097 · Cited by 947
The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism
Kliewer, S. A., Goodwin, B., & Willson, T. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0038 · Cited by 921
Barnes, J., Anderson, L. A., & Phillipson, J. D. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011775910 · Cited by 749
Medicinal Plants and Phytomedicines. Linking Plant Biochemistry and Physiology to Human Health
Briskin, D. P. (2000) · Plant Physiology · doi:10.1104/pp.124.2.507 · Cited by 602
St John's wort for major depression
Linde, K., Berner, M. M., & Kriston, L. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000448.pub3 · Cited by 477
Therapeutic and Medicinal Uses of Terpenes
Cox-Georgian, D., Ramadoss, N., Dona, C., & Basu, C. (2019) · Medicinal Plants · doi:10.1007/978-3-030-31269-5_15 · Cited by 429
Obach, R. S. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39043-3 · Cited by 397
Greeson, J. M., Sanford, B., & Monti, D. A. (2001) · Psychopharmacology · doi:10.1007/s002130000625 · Cited by 379
Mechanism of Action of St John???s Wort in Depression: What is Known?
Butterweck, V. (2003) · CNS Drugs · doi:10.2165/00023210-200317080-00001 · Cited by 369
Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus
Christians, U., Jacobsen, W., Benet, L. Z., & Lampen, A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00003 · Cited by 323
Combining different phases in the development of medical treatments within a single trial
Bauer, P., & Kieser, M. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990730)18:14<1833::aid-sim221>3.0.co;2-3 · Cited by 287
Self-citationSt John's wort: Prozac from the plant kingdom
Di Carlo, G., Borrelli, F., Ernst, E., & Izzo, A. A. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01716-8 · Cited by 277
Potential medicinal plants for CNS disorders: an overview
Kumar, V. (2006) · Phytotherapy Research · doi:10.1002/ptr.1970 · Cited by 268
Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/MS
Tatsis, E. C., Boeren, S., Exarchou, V., Troganis, A. N., Vervoort, J., & Gerothanassis, I. P. (2007) · Phytochemistry · doi:10.1016/j.phytochem.2006.11.026 · Cited by 260
Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For Depression (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01377.x · Cited by 257
Herbal products: Active constituents, modes of action and quality control
Wills, R. B. H., Bone, K., & Morgan, M. (2000) · Nutrition Research Reviews · doi:10.1079/095442200108729007 · Cited by 165
Herbal medicines in the treatment of psychiatric disorders: a systematic review
Sarris, J. (2007) · Phytotherapy Research · doi:10.1002/ptr.2187 · Cited by 164
Evaluating the safety of St. John's Wort in human pregnancy
Moretti, M. E., Maxson, A., Hanna, F., & Koren, G. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.02.003 · Cited by 54
Metadata
- Authors
- Laakmann, G., Schüle, C., Baghai, T., & Kieser, M.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 1998-06
- Volume
- 31
- Issue
- S 1
- Pages
- 54-59
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W2051913494
- Cited by
- 339
- References
- 0
- FWCI
- 34.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.